All Stories

Cellares' cell therapy factory-in-a-box scores coveted ...

Cellares’ automated cell therapy production platform, known as the Cell Shuttle,...

Regulatory tracker: Apellis picks up FDA priority revie...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

Axsome's Sunosi comes up short in trial but shows promi...

A week after reporting a successful phase 3 trial of Sunosi (solriamfetol) in pa...

Regulatory tracker: FDA signs off on freeze-dried versi...

In this tracker, Fierce Pharma is recording the regulatory progress of in-market...

#FierceMadness: Syfovre’s Henry Winkler faces Airsupra’...

As the college basketball March Madness tournament gets underway, so too does Fi...

Lilly continues full-court press against breast cancer ...

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aimi...

Lilly continues full-court press against breast cancer ...

As the women’s NCAA March Madness tournament draws to a close, Eli Lilly is aimi...

DC court backs HHS in rejecting Vertex's proposed ferti...

A District Court backed the U.S. government in its ruling that Vertex's fertilit...

After dismissal of 3rd bankruptcy settlement, Johnson &...

With the decision of a Texas federal judge to dismiss Johnson & Johnson's third ...

Pharma majors put lobbyists to work to stagger tariff r...

As President Donald Trump threatens to impose sweeping geographic tariffs this w...

Switzerland's SHL Medical debuts $220M autoinjector pla...

Drug delivery specialist SHL Medical opened the doors to its new $220 million au...

FDA's new commissioner Marty Makary signed off on Peter...

Peter Marks, M.D., Ph.D., a target for RFK Jr. and allies, last week turned in h...

Pharma's reputation would improve if drugmakers offered...

Patients are looking to pharmaceutical companies to offer healthcare services be...

Another big payday for Daniel O’Day as Gilead boosts hi...

Gilead CEO Daniel O’Day saw another rise in his pay in 2024, reflecting the stea...

Eli Lilly's Alzheimer's contender Kisunla gets thumbs-d...

After failing to pass muster with England’s drug reimbursement watchdog earlier ...

AstraZeneca bulks up Imfinzi's prowess with FDA nod in ...

Imfinzi is the first immunotherapy cleared in the U.S. to treat muscle-invasive ...

FDA reviews Novo Nordisk's bid to expand Rybelsus as or...

The FDA has accepted Novo Nordisk's application for a label expansion for oral G...

Judge levies $1.64B penalty on Johnson & Johnson in HIV...

Nearly a year after a jury decided that Johnson & Johnson should be fined just o...

As FDA's Peter Marks resigns, industry watchers size up...

In resigning as director of the FDA’s Center for Biologics Evaluation and Resear...

As FDA's Peter Marks resigns, industry watchers eye vac...

In resigning as director of the FDA’s Center for Biologics Evaluation and Resear...

Merck's Winrevair slashes mortality-morbidity risk by 76%

Merck revealed data from a phase 3 study of pulmonary arterial hypertension drug...

Bluebird bio receives rival M&A bid worth 50% higher th...

A rival bidder has emerged to acquire struggling gene therapy specialist bluebir...

Lilly adds Alzheimer's disease care to DTC telehealth p...

Eli Lilly is expanding its menu of direct-to-consumer healthcare offerings. The ...

#FierceMadness: AstraZeneca battles itself in Final Fou...

As the college basketball March Madness tournament gets underway, so too does Fi...

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.